| |
|
|
|
Edgemont Capital Partners to Attend 17th Annual Partnerships with CROs
Conference in Las Vegas, April 14-16

NEW YORK, NY, March 1, 2008
|
Edgemont Capital Partners is please to announce that it will
participate in the 17th Annual Partnerships with CROs Conference being
held at the Mandalay Bay Resort & Casino in Las Vegas, Nevada on
April 14th through the 16th.
|
Read the complete press release
Vince and Associates Clinical Research Partners with Private Equity Firm
Celerity Partners

Overland Park, KS, November 14, 2007
Vince and Associates Clinical Research (VNA), a leading independent provider of clinical trial services to the global pharmaceutical and biotechnology industry, announced today it has partnered with private equity investor Celerity Partners (Celerity).
|
Read the complete press release
United Drug Acquires Alliance Health, U.S.-Based Pharmaceutical Sales and Marketing Services Company
Dublin and London, October 15, 2007
United Drug Plc, a leading provider of services to healthcare manufacturers and pharmaceutical retailers in Ireland the UK and Continental Europe today announced that it has acquired the entire issued share capital of Alliance Healthcare Information Inc (“Alliance”) based in Ivyland, Pennsylvania. |
Read the complete press release
Premier Research Group Acquires ARS Inc.
Acquisition Expands Depth and Breadth of Offerings
London, July 13, 2007
Premier Research Group plc (AIM: PRG) the international pharmaceutical services group today announced the acquisition of ARS Inc. The acquisition continues the Company’s stated strategy of building an international business both organically and through strategically placed acquisitions. |
Read the complete press release
IMS Acquires ValueMedics Research in the U.S., Extending Capabilities to Demonstrate Value of Medicines
Expanded Global Health Economics and Outcomes Research Expertise Delivers Critical, Evidence-Based Analysis to Clients for Advancing Healthcare
Norwalk, CT, March 19, 2007
IMS Health (NYSE: RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the acquisition of ValueMedics Research LLC, another step in expanding its global capabilities to help clients demonstrate the value of medicines in advancing healthcare worldwide. ValueMedics, a leading healthcare research and consulting firm based in Falls Church, Virginia, significantly extends IMS’s Health Economics and Outcomes Research (HEOR) expertise in the United States. Terms of the transaction were not disclosed.
|
Read the complete press release
MedGenesis Raises $2.8 million Seed Round, Retains Edgemont Capital Partners to raise $15M Series A

Canadian drug start-up MedGenesis Therapeutix Inc. has raised $3.2 million ($2.8 million) in seed financing and is laying the groundwork for a $15 million Series A next year.
Victoria, British Columbia, November 8, 2006
Erich Mohr, chairman and chief executive of MedGenesis, said the seed round came from high net worth individuals, mostly within the U.S.
Mohr said that MedGenesis has just retained Edgemont Capital Partners of New York to place the Series A, which he expects to come largely from venture capital firms, although he has received interest from existing individual backers. The round is expected to close by mid-2007.
Based in Victoria, B.C., MedGenesis was founded in February with technology licensed from the University of California.
|
Read the complete press release
Constella Group to Acquire Research Triangle Park Contract Research Organization

Acquisition of Lineberry Research Associates to Expand Constella's U.S. Regulatory Affairs and Product Development Services
Durham, NC, October 19, 2006
Constella Group, a leading global provider of professional health services, announced today that it has signed a definitive agreement to acquire Lineberry Research Associates (LRA), a full-service, U.S. contract research organization and consulting firm based in Research Triangle Park, N.C.
Founded in 1995, LRA is a leading provider of regulatory affairs, medical writing, product development strategy, clinical trial management and data management services for pharmaceutical and biotechnology companies. LRA employs more than 75 people, all of whom will join Constella's pharmaceutical product development business unit once the acquisition is complete, which is expected to occur within the next 30 days. |
Read the complete press release
PAREXEL Agrees to Acquire California Clinical Trials Medical Group, Inc., and Behavioral and Medical Research, LLC

Acquisition Adds West Coast Phase I Unit and Specialty Phase II – IV Clinical Research Services
Boston, MA, October 12, 2006
PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services organization, today announced the execution of a definitive purchase agreement to acquire the business and operations of California Clinical Trials Medical Group, Inc. (“CCT”) and Behavioral and Medical Research, LLC (“BMR”). Established in 1981 with headquarters in San Diego, CCT and BMR provide a broad range of specialty Phase I – IV clinical research services through four clinical sites in California. The purchase price is $65 million, and the acquisition is expected to close within the next thirty days. |
Read the complete press release
Questcor Announces the Acquisition of Doral(R) (quazepam); Provides Second Product for National Neurology Sales Force

Union City, CA, May 5, 2006
Questcor Pharmaceuticals, Inc. (AMEX:QSC) today announced the acquisition of U.S. rights to Doral(R) (quazepam), a non-narcotic, selective benzodiazepine receptor agonist that is indicated for the treatment of insomnia, characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Questcor is acquiring the product from MedPointe Inc. for $2.5 million in cash and a future milestone payment of $1.5 million. Gross ex-factory sales for Doral in 2005 were $1.1 million.
"Sleep disturbance and insomnia is a very common side effect of many, if not most, neurological diseases and disorders such as Multiple Sclerosis, Epilepsy, Parkinson's disease, and Alzheimer's disease and is a critical concern of Questcor's targeted physicians. We believe that Doral will complement our efforts to expand the prescribing of our lead product, H.P. Acthar(R) Gel (repository corticotropin injection), and will allow Questcor to significantly leverage our forty person national neurology sales force," said Jim Fares, President and CEO of Questcor. |
Read the complete press release
Azur Pharma Acquires Gastrocrom®

Dublin, Ireland, January 18, 2006
Azur Pharma Limited (“Azur Pharma”) today announced that it has acquired the U.S. rights to Gastrocrom® (cromolyn sodium, usp Oral Concentrate) from UCB Pharma, Inc (“UCB”). Gastrocrom® is indicated in the management of patients suffering from mastocytosis, a rare disorder characterized by an abnormal accumulation of mast cells in various organ systems. Annual sales of Gastrocrom® amount to approximately US$5 million.
“I am pleased to announce our first product acquisition, Gastrocrom®, a mature and stable prescription product indicated for a rare and often chronic disorder. This acquisition is an important first step as we seek to execute on our mission of creating a U.S. pharmaceutical business focused on developing and marketing products in specialist therapeutic areas.” commented Mr. Seamus Mulligan, Azur Pharma’s Chairman and Chief Executive Officer. |
|
|
|
|
|
 |
|
 |
 |
Edgemont Capital Partners advises Questcor Pharmaceuticals on the sale
of its Nascobal® product line to QOL Medical
Union City, CA, October 17, 2005
| Questcor Pharmaceuticals, Inc. (AMEX:QSC), a specialty pharmaceutical
company that develops and commercializes novel therapeutics for
the treatment of neurological disorders, today announced the completion
of a transaction to divest its non-core pharmaceutical products,
in accordance with its new central nervous system (CNS) strategy.
Questcor completed the sale of its Nascobal(R), Ethamolin(R) and
Glofil(R)-125 products to QOL Medical LLC for $28.3 million, plus
the assumption by QOL of the obligation to pay Nastech Pharmaceutical
Company Inc. (NasdaqNM: NSTK) $2 million on the issuance by the
US Patent and Trademark Office of a patent on Nascobal Nasal Spray. |
Read
the complete press release
Edgemont Capital Partners advises MedSN on merger with
Indegene
Los Angeles, CA, and Bangalore, India / September 13, 2005
| MedSN, Inc., a leading medical education, sales training, and marketing services
provider based in the United States, today announced that it has merged with the
Indegene group of companies, the preeminent medical education, training, and marketing
services provider in India and Asia. |
Read
the complete press release
Edgemont Capital Partners advises Hollister-Stier Laboratories
on the divestiture of its Twinject™ allergy product line to Verus Pharmaceuticals
San Diego, CA, July 06, 2005
Verus Pharmaceuticals, Inc., a pediatric-oriented company dedicated
to identifying, developing and delivering solutions to address the
unmet medical needs of children and those who care for them, today
announced it has acquired exclusive, worldwide rights to Twinject™
from Hollister-Stier Laboratories LLC. Twinject, a novel epinephrine
auto-injector indicated for the emergency treatment of severe allergic
reactions (anaphylaxis), was approved by the U.S. Food and Drug
Administration (FDA) in 2003; two dosages are now approved for self-administration
(0.3 mg and 0.15 mg). In addition to Twinject, Verus has acquired
rights to other intellectual property and assets, including complementary
and next generation device designs and on-going development programs.
Edgemont Capital Partners acted as exclusive financial advisor to
Hollister-Stier Laboratories. |
Read
the complete press release
Edgemont Capital Partners advises PharmAnalysis Group, Inc. on its acquisition
by United BioSource Corp.
Bethesda, MD, August 09, 2004
| MEDTAP® International, Inc. (a subsidiary of United BioSource Corp.) announced
today that it has broadened its research and consultation services to include
strategic reimbursement planning through the addition of PharmAnalysis Group,
Inc., a provider of reimbursement planning for the pharmaceutical, biotechnology,
medical device and diagnostics industries, as MEDTAP's new Center for Pricing
and Reimbursement. With this addition, MEDTAP, a global research organization
specializing in outcomes research, economic evaluation and policy research, adds
strategic consulting in pricing and reimbursement to its array of existing services. |
Read
the complete press release
Edgemont Capital Partners advises POZEN on the licensing of MT 300 to
Xcel Pharmaceuticals
Chapel Hill, NC & San Diego, CA, September 04, 2003
| POZEN Inc. (NASDAQ: POZN) and Xcel Pharmaceuticals, Inc. (Xcel) announced
today that they have signed an agreement for the commercialization of MT 300(TM)
that may provide a new and effective injectable treatment for patients suffering
from severe migraine headaches. MT 300 is being developed as an improved and highly
purified formulation of dihydroergotamine mesylate (DHE) in a convenient pre-filled
syringe that is suitable for at-home use. As previously announced, POZEN submitted
a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for
marketing approval of MT 300 on December 17, 2002. The application is currently
under review at the FDA. |
Read
the complete press release
Desitin Retains Edgemont Capital Partners as Exclusive
Financial Advisor And Representative
Hamburg, & New York City, August 08, 2003
| Desitin Arzneimittel
GmbH and Edgemont Capital Partners today announced that Desitin has engaged Edgemont
as its exclusive financial advisor and representative. Edgemont will work to secure
a U.S. commercialization partner for the Company's novel, once- daily, sustained
release oral formulation of oxcarbazepine. Oxcarbazepine is currently marketed
in the U.S. exclusively by Novartis under the brand name Trileptal(tm) as a twice-a-day
therapy for the treatment of epilepsy, and had U.S. sales of $212 million in 2002. |
Read the complete press release
Edgemont Capital Partners advises Nastech Pharmaceutical Company on the sale of
the Nascobal® product line
Bothell, WA, June 17, 2003
| Nastech Pharmaceutical Company, Inc. (Nasdaq: NSTK), a leader in nasal drug
delivery technology, announced today that Questcor Pharmaceuticals, Inc. (Amex:
QSC) is acquiring Nastech's Nascobal® product, including the FDA- approved
Nascobal® (Cyanocobalamin USP) nasal gel and the Nascobal® nasal spray,
which is pending FDA approval. The transaction includes all Nascobal® intellectual
property, marketing rights, inventory, trademarks, confidential know-how, contracts,
and records.
Edgemont Capital Partners has acted as Nastech's investment banking advisor
on this transaction. |
Read
the complete press release
Managing Director David Blume is interviewed by The Wall Street Transcript
NY, March 2003
Click here to read David's interview (Requires Acrobat Reader. Get it here.)
Edgemont Capital Partners advises CroMedica, Inc. on merger with PRA
International, Inc.
McLean, VA, June 17, 2002
| PRA International Inc, a pharmaceutical research industry leader in contract clinical development services, today announced that it has agreed to a merger with CroMedica International, Inc, a worldwide clinical research organization (CRO) headquartered in Canada. The combined companies will operate under the PRA International name, forming one of the top five global clinical drug development organizations. |
|
 |
 |
 |
 |